New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
08:32 EDTCBPOChina Biologic announces favorable resolution to title dispute
China Biologic announced that the company has learned that the pending claim in the High Court of Hong Kong against Siu Ling Chan, an individual shareholder of the company, and her spouse, Tung Lam, had been withdrawn with Court approval. The claim was originally filed by a group of individuals against the title of certain shares of the company's common stock held by Chan and Lin Ling Li, a formal individual shareholder of the company. The company understands that the plaintiffs have reached settlement agreements with all defendants, including Chan and her spouse, with respect to the claim, and the claim against other defendants, Li and her spouse, had also previously been withdrawn with Court approval. The withdrawal of the claim against Chan and her spouse with Court approval thus represents a final conclusion to the title dispute in respect of certain shares of the Company's common stock held by Chan and Li.
News For CBPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
08:35 EDTCBPOChina Biologic enters into collaboration agreement to source raw materials
China Biologic announced that the company's subsidiary Guizhou Taibang Biological Products entered into a strategic collaboration agreement with Xinjiang Deyuan Bioengineering to source raw plasma. The Agreement allows Guizhou Taibang to source no less than 500 tonnes of source plasma from Xinjiang Deyuan over the next three years. The raw plasma will be shipped in batches to Guizhou Taibang for the production of human albumin and IVIG products. The company expects that the products made from the sourced raw plasma will begin to reach the market in second half of 2016. As required and approved by the local regulator, during the term of the Agreement, Xinjiang Deyuan will entrust the operation of its plasma collection stations to Guizhou Taibang. As part of the Agreement, Guizhou Taibang agreed to lend to Xinjiang Deyuan an interest-bearing loan with a principal amount of approximately $47M). The loan is due July 31, 2018 and is secured by a pledge of a 58.02% equity interest in Xinjiang Deyuan from its controlling shareholder. The loan to Xinjiang Deyuan and the raw plasma will be funded primarily by the Company's cash released from a collateral deposit to secure a USD-denominated loan that the Company repaid in full in June 2015.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use